drugset / Trial / NCT01632566

A Multiple-dose Study of LY3031207 in Healthy Participants

NCT01632566

Phase 1 Terminated 39 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to healthy Japanese and non-Japanese participants as multiple doses. In addition, effects of 28-day oral dosing of LY3031207 on the amount of a cholesterol-lowering drug (simvastatin) that gets into the blood stream and how long the body takes to get rid of it will be determined. The effects of LY3031207 after single and 28-day dosing on blood pressure will also be studied. Information about any side effects that may occur will be collected.

Timeline

Start
2012-06
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 400 mg Oral
Subject LY3031207 Small molecule 25 mg Oral
Subject LY3031207 Small molecule 75 mg Oral
Subject LY3031207 Small molecule 225 mg Oral
Subject LY3031207 Small molecule 450 mg Oral
Subject Simvastatin Small molecule 10 mg Oral

Indications

No indication recorded.